We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Celgene has presented Revlimid clinical data from a multicenter Phase II trial
evaluating Revlimid in patients with low and intermediate-1 risk myelodysplastic
syndromes.
Exelixis has signed a collaboration agreement with Genentech for the discovery
and development of therapeutics to target cancer, inflammatory diseases, and
tissue growth and repair.
AVI BioPharma presented positive results from two preclinical studies at the
87th Annual Meeting of the Endocrine Society being held in San Diego June 4-7,
2005.
Bioenvision has announced that results from clinical trials of clofarabine in
adult AML were presented at the 10th European Hematology Association meeting
in Stockholm, Sweden.
Kosan Biosciences has initiated a company-sponsored multicenter Phase I clinical
trial of KOS-1022 (DMAG) in patients with advanced hematologic malignancies.
CollaGenex Pharmaceuticals has announced positive results from two Phase III,
double-blinded, placebo-controlled clinical trials designed to evaluate the
safety and efficacy of Oracea for the treatment of rosacea, a common but little-known
disorder of the facial skin.
Oscient Pharmaceuticals has completed preliminary data analysis of its pivotal
Phase III trial examining the potential use of Factive (gemifloxacin mesylate)
tablets for the five-day treatment of mild to moderate community-acquired pneumonia
(CAP).